6-Month Outcomes of PEMF to Nucleotide Sources Revealing Cell Sensory Experience in Pain Relief, Stress Relief and Anti Ageing Restoration
NCT ID: NCT04461470
Last Updated: 2020-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2019-08-29
2024-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hz Clinic registry is a programme made of five scheduled cohorts designed to include participants dealing with Immunity compromise, Pain, Ageing and Stress (general and pandemic anxieties) who are to be followed for 6 month to five years in their structured routine of pulsed electro resonance (PEMF) to determine their clinical outcome in the real world, contributing evidence for benchmarking fellow cohort participant variance.
Here we report baseline characteristics, PEMF transfer events and outcomes in participants in the UK. This study serves as a calibration proforma for downstream real world evidence observations of PEMF in the field.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulsed Electromagnetic Fields in Preventing Physical Deconditioning in Patients Undergoing Prolonged Hospitalization
NCT06744764
Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)
NCT03333135
PEMF Stimulation on Physical Exercise in Sedentary People
NCT06446466
Effects of Extracorporeal Shock Wave Therapy and Pulse Electromagnetic Field Therapy on Lymphoedema
NCT06041958
Pulsed Shortwave Therapy for Postoperative Analgesia
NCT05796583
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Electro resonance (PEMF) therapy is relatively new, despite the fact that it is considered a gold standard approach in healthcare application.
The base premise of PEMF is to apply field (inducing force) energies to a host, producing a spectrum of physiological benefits (Bagnato et al., 2015). The advantages of PEMF approaches are the vast modalities available in which an inducing force is applied and is configured (low to high hz intensity, frequency and polarity). The disadvantages are, however, dissonances in paradigm trajectory and PEMF seldom interrogation of the in-situ / in-vivo metrics of change in recipient (Funk et al., 2008; Peterchev et al., 2012).
PEMF data in healthcare enables an exercise of compelled judgement(s) across all critical level (pre-clinical, phase I, phase II, phase III, phase IV) system activity. Today there is an apparent disjoint of insight between systems-derived data (imaging) and treatment applied data (remedial action). Some example settings of this include i) electro resonance / surgery as an evidence based tool in clinical decision making (Phelps et al., 2018 and Strauch et al., 2009); ii) in-vitro electro resonance in skin equivalence model (Mitchell et al., 2015 and Mitchell et al., 2016) and bone stimulus model (Ferroni et al., 2018) modelling in-vivo benefit; iii) phase IV anticoagulation and prothrombin ratio 'observations and stratification' using principle component positions, and observing all contributing variances in play (Sawhney et al., 2018).
The unprecedented contribution of pandemic variance (Huang et al., 2020), is heightening a public awareness of how manifold real world evidence is in resolving the insight disjoints. Biomedical problems occur in forms where remote or aseptic application and self observation is paramount to care; particularly in the cases of infection, healing wounds and hydro-electrolyte restoration(s).
In plentiful coverage, PEMF homeostatic benefits on Immunity compromise, Pain, Stress and Ageing are extensively reviewed with Mun et al., (2018); and although the mechanisms of actions are underpinned; our literature search shows that there are seldom real world initiatives, recording wide-spread physiological improvements that PEMF therapy enacts.
Aim:
Here we describe the calibration proforma of PEMF correspondence scoring in longitudinal, physiological and observational outcomes. This study will serve as method development for downstream real world evidence observations of PEMF in the field.
Method:
Ethics statement
All participants provided written informed consent in the online basket checkout at hzclinic.co.uk opting to be therapy subjects. The registry is being conducted in accordance with local regulatory requirements, and the International Conference on Harmonisation-Good Pharmacoepidemiological and Clinical Practice Guidelines.
Procedures and outcomes measures
Baseline data collected at screening included participant characteristics (like age), type of clinical-problem (Stress, Pain, Immunity compromise), date and method of diagnosis if any formal, symptoms, and PEMF treatment (delocalised resonance over nucleotide source inducing post transcription modification (PTM) to ubiquitous properties (U.P.)) 2 hz PTM; 3 hz PTM; 4 hz PTM; 5 hz PTM \[request appendix for additional I.P. support\].
Data on all components of (and) the McGill Life (Sensory, Affectory, Evaluative, Miscellaneous) Index Chart (recordings) were collected to assess the sensitivities of Pain, Stress, Ageing and Immunity compromise states retrospectively.
hz data were collected using a proprietary electronic case report form (eCRF) captured by trained personnel. Oversight of the operations and data management are managed by the coordinating centre hz Clinic, with supporting entities PropDesk (London, UK) and East London Electric Company (ELEC) (London, UK); and resourcing centres MedCity in conjunction with UCL Partners, Imperial College Health Partners and the Health Innovation Network.
The hz protocol requires that 20% of all eCRFs are monitored against source documentation, that there is an electronic audit trail for all data modifications, and that critical variables are subjected to additional audit (Cohen et al., 2015).
Statistical analysis
This article describes the baseline characteristics, treatment patterns and 6 month outcomes based on national data and for participants included in the UK; data for these analyses were extracted from the registry database on 12th February 2020. Continuous variables are expressed as mean ± standard deviation (SD) and categorical variables as frequency and percentage. Utility of PEMF at baseline was analysed by McGill Life Chart Index scores, calculated retrospectively from the data collected. Participants with missing values were not removed from the study. National normalised ratio (NNR) readings during the 6 months follow up were included in the analysis. We adapted the international normalised ratio (Bonar and Favaloro., 2016) with the acquisition and processing of urine samples for participant metabolome mass fingerprinting and hydration readings as an index, performed (request appendix for additional NNR guidelines). Implausible NNR value of less than 0.8 or greater than 20 were excluded. The distribution of NNR values are described by counts and percentages below, within, and above the therapeutic range, and by the mean, SD, median, and interquartile range (IQR).
Occurrence of major clinical response (primarily, Pain-relief, Stress-relief, anti-oxidation (/ageing) and quenched inflammation) is described using the number of events, the proportion of participants with the event divided by the population at burden at the beginning of the follow-up-period, person-time event rate (per 100 person-years), and 95% confidence interval (CI). We estimated person-year rates using a Poisson model, with the number of events. Only the first occurrences of each event were taken into account. Data analysis was performed at the PropDesk with MatLab (MathsWorks, Massachusetts, USA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
London
pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
epigenetic longitudinal waves
force - inducing energies using electromagnetic field(s)
All United Kingdom
pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
epigenetic longitudinal waves
force - inducing energies using electromagnetic field(s)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
epigenetic longitudinal waves
force - inducing energies using electromagnetic field(s)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
East London Electric Company
UNKNOWN
PropDesk
UNKNOWN
MedCity
UNKNOWN
UCL Partners
UNKNOWN
Imperial College London Partners
UNKNOWN
Health Innovation Network
UNKNOWN
hz Clinic
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher L Davies
Role: STUDY_CHAIR
East London Electric Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
hz Clinic
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Bagnato GL, Miceli G, Marino N, Sciortino D, Bagnato GF. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial. Rheumatology (Oxford). 2016 Apr;55(4):755-62. doi: 10.1093/rheumatology/kev426. Epub 2015 Dec 24.
Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014 Feb 4;110(3):551-5. doi: 10.1038/bjc.2013.725. Epub 2014 Jan 14. No abstract available.
Ferroni L, Gardin C, Dolkart O, Salai M, Barak S, Piattelli A, Amir-Barak H, Zavan B. Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-alpha mediated inflammatory conditions: an in-vitro study. Sci Rep. 2018 Mar 23;8(1):5108. doi: 10.1038/s41598-018-23499-9.
Funk RH. Coupling of pulsed electromagnetic fields (PEMF) therapy to molecular grounds of the cell. Am J Transl Res. 2018 May 15;10(5):1260-1272. eCollection 2018.
Kolifarhood G, Aghaali M, Mozafar Saadati H, Taherpour N, Rahimi S, Izadi N, Hashemi Nazari SS. Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. Arch Acad Emerg Med. 2020 Apr 1;8(1):e41. eCollection 2020.
Mitchell CA, Long H, Donaldson M, Francese S, Clench MR. Lipid changes within the epidermis of living skin equivalents observed across a time-course by MALDI-MS imaging and profiling. Lipids Health Dis. 2015 Aug 5;14:84. doi: 10.1186/s12944-015-0089-z.
Mitchell CA, Donaldson M, Francese S, Clench MR. MALDI MSI analysis of lipid changes in living skin equivalents in response to emollient creams containing palmitoylethanolamide. Methods. 2016 Jul 15;104:93-100. doi: 10.1016/j.ymeth.2016.02.001. Epub 2016 Feb 2.
Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1.
Osler M, Rozing MP, Christensen GT, Andersen PK, Jorgensen MB. Electroconvulsive therapy and risk of dementia in patients with affective disorders: a cohort study. Lancet Psychiatry. 2018 Apr;5(4):348-356. doi: 10.1016/S2215-0366(18)30056-7. Epub 2018 Mar 6.
Peterchev AV, Wagner TA, Miranda PC, Nitsche MA, Paulus W, Lisanby SH, Pascual-Leone A, Bikson M. Fundamentals of transcranial electric and magnetic stimulation dose: definition, selection, and reporting practices. Brain Stimul. 2012 Oct;5(4):435-53. doi: 10.1016/j.brs.2011.10.001. Epub 2011 Nov 1.
Phelps DL, Balog J, Gildea LF, Bodai Z, Savage A, El-Bahrawy MA, Speller AV, Rosini F, Kudo H, McKenzie JS, Brown R, Takats Z, Ghaem-Maghami S. The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS). Br J Cancer. 2018 May;118(10):1349-1358. doi: 10.1038/s41416-018-0048-3. Epub 2018 Apr 19.
Reid B, Zhao M. The Electrical Response to Injury: Molecular Mechanisms and Wound Healing. Adv Wound Care (New Rochelle). 2014 Feb 1;3(2):184-201. doi: 10.1089/wound.2013.0442.
Sawhney JP, Kothiwale VA, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawla K, Allu J, Pieper KS, John Camm A, Kakkar AK; GARFIELD-AF Investigators. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart J. 2018 Nov-Dec;70(6):828-835. doi: 10.1016/j.ihj.2018.09.001. Epub 2018 Sep 12.
Strauch B, Herman C, Dabb R, Ignarro LJ, Pilla AA. Evidence-based use of pulsed electromagnetic field therapy in clinical plastic surgery. Aesthet Surg J. 2009 Mar-Apr;29(2):135-43. doi: 10.1016/j.asj.2009.02.001.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.